Deya Corzo

Deya Corzo, MD

Assistant in Medicine

Instructor in Pediatrics, Harvard Medical School

    Contact: 617-355-4697
  • Fax: 617-730-0466

Medical Services

Specialties

  • Lysosomal Storage Diseases and Disorders
  • Dysmorphology
  • Pediatrics
  • Clinical Genetics

Departments

  • Genetics and Genomics
  • Medicine

Languages

  • Spanish

Programs

  • Genetics Program
To schedule an appointment: Call 617-355-4697 or Request an Appointment

Experience and Education

Education

Industrial University of Santander, 1991

Residency

Maimonides Medical Center, 1998

Brooklyn, NY

Postdoctoral Research Fellow in Pathology

Dana Farber Cancer Institute, 1995

Boston, MA

Fellowship, Genetics

Boston Children's Hospital , 2001

Boston, MA

Certifications

  • Pediatrics, Genetics

Publications

Publications powered by Harvard Catalyst Profiles
  1. Liang C, Li L, Fraser CD, Ko A, Corzo D, Enger C, Patt D. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. BMC Cancer. 2015; 15:1019.
  2. Rodrigues R, Artieda M, Tejedor D, Martínez A, Konstantinova P, Petry H, Meyer C, Corzo D, Sundgreen C, Klor HU, Gouni-Berthold I, Westphal S, Steinhagen-Thiessen E, Julius U, Winkler K, Stroes E, Vogt A, Hardt P, Prophet H, Otte B, Nordestgaard BG, Deeb SS, Brunzell JD. Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency. J Clin Lipidol. 2016 Mar-Apr; 10(2):394-409.
  3. Patt D, Rembert D, Corzo D. Treatment of metastatic breast cancer with ??????-paclitaxel in the community practice setting: a US Oncology survey. J Community Support Oncol. 2015 May; 13(5):173-80.
  4. Andersen EF, Carey JC, Earl DL, Corzo D, Suttie M, Hammond P, South ST. Deletions involving genes WHSC1 and LETM1 may be necessary, but are not sufficient to cause Wolf-Hirschhorn Syndrome. Eur J Hum Genet. 2014 Apr; 22(4):464-70.
  5. Garrison LP, Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist. 2013; 18(1):27-36.
  6. van Capelle CI, van der Beek NA, Hagemans ML, Arts WF, Hop WC, Lee P, Jaeken J, Frohn-Mulder IM, Merkus PJ, Corzo D, Puga AC, Reuser AJ, van der Ploeg AT. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord. 2010 Dec; 20(12):775-82.
  7. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010 Apr 15; 362(15):1396-406.
  8. Young SP, Zhang H, Corzo D, Thurberg BL, Bali D, Kishnani PS, Millington DS. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med. 2009 Jul; 11(7):536-41.
  9. Yatsenko SA, Kruer MC, Bader PI, Corzo D, Schuette J, Keegan CE, Nowakowska B, Peacock S, Cai WW, Peiffer DA, Gunderson KL, Ou Z, Chinault AC, Cheung SW. Identification of critical regions for clinical features of distal 10q deletion syndrome. Clin Genet. 2009 Jul; 76(1):54-62.
  10. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GL, Pivnick EK, Ottinger CJ, Robinson PH, Loo JC, Smitka M, Jardine P, Tatò L, Chabrol B, McCandless S, Kimura S, Mehta L, Bali D, Skrinar A, Morgan C, Rangachari L, Corzo D, Kishnani PS. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009 Mar; 11(3):210-9.
  11. Show all
  12. Wokke JH, Escolar DM, Pestronk A, Jaffe KM, Carter GT, van den Berg LH, Florence JM, Mayhew J, Skrinar A, Corzo D, Laforet P. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve. 2008 Oct; 38(4):1236-45.
  13. Smith WE, Sullivan-Saarela JA, Li JS, Cox GF, Corzo D, Chen YT, Kishnani PS. Sibling phenotype concordance in classical infantile Pompe disease. Am J Med Genet A. 2007 Nov 1; 143A(21):2493-501.
  14. Wang LY, Ross AK, Li JS, Dearmey SM, Mackey JF, Worden M, Corzo D, Morgan C, Kishnani PS. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. Paediatr Anaesth. 2007 Aug; 17(8):738-48.
  15. Kallwass H, Carr C, Gerrein J, Titlow M, Pomponio R, Bali D, Dai J, Kishnani P, Skrinar A, Corzo D, Keutzer J. Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots. Mol Genet Metab. 2007 Apr; 90(4):449-52.
  16. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007 Jan 9; 68(2):99-109.
  17. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006 May; 148(5):671-676.
  18. Haley SM, Ni P, Fragala-Pinkham MA, Skrinar AM, Corzo D. A computer adaptive testing approach for assessing physical functioning in children and adolescents. Dev Med Child Neurol. 2005 Feb; 47(2):113-20.
  19. Hunley TE, Corzo D, Dudek M, Kishnani P, Amalfitano A, Chen YT, Richards SM, Phillips JA, Fogo AB, Tiller GE. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics. 2004 Oct; 114(4):e532-5.
  20. Lombardi VR, Fernández-Novoa L, Corzo D, Zas R, Cacabelos R. Enhancement in immune function and growth using E-JUR-94013 supplementation. Methods Find Exp Clin Pharmacol. 2002 Nov; 24(9):573-8.
  21. Corzo D, Gibson W, Johnson K, Mitchell G, LePage G, Cox GF, Casey R, Zeiss C, Tyson H, Cutting GR, Raymond GV, Smith KD, Watkins PA, Moser AB, Moser HW, Steinberg SJ. Contiguous deletion of the X-linked adrenoleukodystrophy gene (ABCD1) and DXS1357E: a novel neonatal phenotype similar to peroxisomal biogenesis disorders. Am J Hum Genet. 2002 Jun; 70(6):1520-31.
  22. Alvarez XA, Pichel V, Pérez P, Laredo M, Corzo D, Zas R, Fernández-Novoa L, Sempere JM, Díaz J, Cacabelos R. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Methods Find Exp Clin Pharmacol. 2000 Sep; 22(7):585-94.
  23. Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ, Yunis EJ. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood. 1997 Jun 1; 89(11):4167-74.
  24. Alvarez XA, Laredo M, Corzo D, Fernández-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol. 1997 Apr; 19(3):201-10.
  25. Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood. 1995 Nov 15; 86(10):3835-40.
  26. Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ. HLA associations in clozapine-induced agranulocytosis. Blood. 1995 Aug 1; 86(3):1177-83.
  27. Corzo D, Salazar M, Granja CB, Yunis EJ. Advances in HLA genetics. Exp Clin Immunogenet. 1995; 12(3):156-70.
  28. Corzo D, Yunis JJ, Yunis EJ, Howard A, Lieberman JA. HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. J Clin Psychiatry. 1994 Sep; 55 Suppl B:149-52.
  29. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, Herman GE, Amalfitano A, Thurberg BL, Richards S, Davison M, Corzo D, Chen YT. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006 Jul; 149(1):89-97.
  30. Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, Bauer MS, Jokic M, Tsai CE, Tsai BW, Morgan C, O'Meara T, Richards S, Tsao EC, Mandel H. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009 Sep; 66(3):329-35.
  31. Case LE, Hanna R, Frush DP, Krishnamurthy V, DeArmey S, Mackey J, Boney A, Morgan C, Corzo D, Bouchard S, Weber TJ, Chen YT, Kishnani PS. Fractures in children with Pompe disease: a potential long-term complication. Pediatr Radiol. 2007 May; 37(5):437-45.
To schedule an appointment: Call 617-355-4697 or Request an Appointment

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close